

Ching-Hsuan Lin, MD, MPH¹; Tara A. Lavelle, PhD¹; Marie C. Phillips, BA¹; Abigail G. Riley, BA¹; Daniel A. Ollendorf, PhD¹
Tufts Medical Center, Boston, MA, USA

Poster Code: PCR63
Ching-Hsuan.Lin@tuftsmedicine.org

Background & Objectives

- Measures of health gain inform drug pricing and policy decisions
- These measures affect community members, yet prior studies have not documented their opinions on the measures
- We investigated community members' attitudes on health gain measures in a live deliberation

Methods

- We recruited 20 stakeholders from the Boston area, including patients, caregivers, citizens, clinicians, and pharmacy/allied health professionals
- We provided educational materials and sessions on nine health gain measures to the participants
- We hosted two in-person deliberation sessions. During and after the sessions, we:
 - Conducted deliberations and ranking exercises separately within two groups and then together as a large group
 - Recorded the deliberations and conducted a qualitative analysis that structured discussions into broad themes
 - Developed a user-friendly dashboard featuring the top three health gain measures

Results

Health Gain Measure Rankings:

	Patients and caregivers	Citizens, clinicians, and pharmacy/allied health professionals	Final ranking
QALY (Quality-Adjusted Life Year)	1	2	1
Clinical Benefit	2	3	2
MCD (Multi-Criteria Decision Analysis)	6	1	3
Added Benefit	4	5	4
SROI (Social Return On Investment)	9	4	5
DALY (Disability-Adjusted Life Year)	5	8	6
HYT (Health Years in Total)	8	6	7
evLY (Equal Value Life Years)	3	7	8
LY (Life Year)	7	9	9

Top-three Discussed Themes:

- Patient input is important for deriving values in population-based health gain measures
- Need multiple complementary measures to see full range of societal benefits
- Information should be accessible, simple, and understandable to the public

Dashboard Example: Resmetirom vs. Lifestyle Management for Non-alcoholic Steatohepatitis

Background Information

Resmetirom is a pill you take once a day. Clinical studies showed that adding resmetirom to lifestyle management (exercise, improved diet, etc.) improved quality of life and helped keep NASH from getting worse compared to lifestyle management alone. The most common side effect was moderate itching.

Clinical Benefit

How beneficial is it?	How sure are we?	Should the treatment be used?
Large or medium benefit	Sure or very sure	Recommend use
Small benefit	Sure or very sure	Might recommend use
Undetermined benefit	Unsure	Inconclusive
No benefit	Sure or very sure	Discourage use

Quality-Adjusted Life Years (QALYs)

Multi-Criteria Decision Analysis (MCDA)

What Does This Mean For Most Patients?

- Adding resmetirom to lifestyle management will improve your health by a **medium to large** amount
- There is **confidence** in this result based on strong evidence from a clinical trial of nearly 1,000 patients
- Use of this drug is **recommended**

- Adjusted for the quality of your life, resmetirom adds about **7.5 months** compared to lifestyle management
- This comes from an extra 6 months in how long you will live and a small gain in your quality of life
- Compared to other treatments in NASH and other diseases, this is considered a **substantial improvement**

- Resmetirom is rated very or somewhat **favorably** on all important value factors
- Health gains were considered **equal** across patient groups
- The overall rating is **favorable** for using this drug in appropriate patients

Other Important Information:

You should take resmetirom along with the lifestyle management changes your doctor recommends. You do not need any special monitoring or extra doctor visits to continue taking this drug. However, please consult with your doctor before taking resmetirom.

Conclusions

- The QALY is the most preferred health gain measure in our multi-stakeholder deliberation
- Other measures provided important complementary information that should be presented alongside the QALY, particularly since patient preferences were an important foundation